The Management of Melanoma during the COVID-19 Pandemic: A Single Institutional Experience

Ciaran Hurley, SpR

Department of Plastic and Reconstructive Surgery

Galway University Hospital



Introduction

- The COVID-19 pandemic has been unprecedented and led to drastic reductions in urgent plastic surgery elective activity.
- Locally, in Galway University Hospital, elective clinics and theatre lists were cancelled. Urgent cancer care was delivered via private hospitals. Delayed access to theatre and the restructuring of plastic surgery services altered the triage and management of skin cancers worldwide.
- We aimed to provide a comparative analysis focused on the diagnosis and management of both invasive and non-invasive melanoma before and during the COVID-19 pandemic in Ireland.

Methods

- A single-centre retrospective review of 589 patients with invasive and non-invasive melanoma in 2019 and 2020 was conducted.
- Patient demographics, tumour subtype and characteristics, sentinel node status, lymphadenectomy status, radiology and systemic oncological therapies were collected.
- Statistical analysis was performed using R v 3.6.3. Counts and percentages were used to summarize the distribution of categorical variables. The mean ± standard deviation (SD) and the median/interquartile range (IQR) were used to summarize the distribution of continuous normal and non-normal variables, respectively.
- Chi-square test of independence was used to assess the association between categorical variables.
- Unpaired t-test and Mann-Whitney test were used to compare the distribution of normal and non-normal variables between groups, respectively. Hypothesis testing was performed at 5% level of significance.



Results

- 589 patients were included
 - Mean age=65.6 (SD=16.2)
 - Male n=283 (48%) Female n= 306 (52%)
- 2019 (prior to COVID-19) n=277
 - Invasive n=129 (46.6%)
 - Non-invasive *n*=148 (53.4%)
- 2020 (during pandemic) n=312
 - Invasive n=185 (59.3%)
 - Non-invasive n=127 (40.7%)
- In 2019, the mean number of days from GP referral to excisional biopsy was **28.2** days. This increased to **64.3** days in 2020 (p=0.037)
- External referrals from GP's decreased signficantly during the pandemic, and increased from dermatologists (p=0.001)

Table 1. Referral and Subtype

| | 2019 | 2020 |
|--------------------|-------------|-------------|
| | n=277 | n=312 |
| Referral to Biopsy | 28.2 (24.6) | 64.3 (69.6) |
| Referred From | | |
| GP | 231 (83.4%) | 179 (60.5%) |
| Dermatology | 35 (12.6%) | 94 (31.8%) |
| Surgery | 11 (3.97%) | 22 (7.43%) |
| Medical | 0 (0.00%) | 1 (0.34%) |
| Subtype | | |
| In situ | 148 (53.4%) | 127 (43.6%) |
| SS | 75 (27.1%) | 90 (30.9%) |
| Nodular | 29 (10.5%) | 38 (13.1%) |
| LMM | 10 (3.61%) | 19 (6.53%) |
| Acral | 9 (3.25%) | 9 (3.09%) |
| Amelanotic | 0 (0.00%) | 1 (0.34%) |
| Spindle | 2 (0.72%) | 5 (1.72%) |
| Naevoid | 0 (0.00%) | 1 (0.34%) |
| Mixed SS/ nodular | 0 (0.00%) | 1 (0.34%) |
| Recurrent | 3 (1.08%) | 0 (0.00%) |
| Spitzoid | 1 (0.36%) | 0 (0.00%) |
| | | |

SS=superficial spreading; LMM=lentigo maligna melanoma



Results

- The average Breslow thickness was not significantly different between 2019 and 2020 (*p*=0.229)
- More patients required a sentinel node biopsy in 2020 compared to 2019 (p=0.018).
- Of these, 56.2% were positive in 2019 compared to 23.7% in 2020 (*p*=0.001).
- No statistically significant difference was observed in the average deposit size between 2019 and those in 2020 (p = 0.365).
- The proportion of the patients that had a completion lymphadenectomy was not significantly different between groups.
- No difference was noted in negative tumour characteristics such as perineural invasion, lymphovascular invasion, ulceration, microsatellites and mitosis (p=0.662)

Table 2. Tumour characteristics, surgery, and oncology

| | 2019 2020 | | p |
|---------------------------|-------------|-------------|-----------------------|
| | n=129 | n=185 | |
| Breslow thickness SLNB | 3.10 (3.68) | 2.60 (3.16) | 0.229 0.018 |
| Not performed | 79 (61.2%) | 87 (47.0%) | |
| Performed | 50 (38.8%) | 98 (53.0%) | |
| Nodal Status | | | <0.001 |
| Negative | 21 (43.8%) | 68 (73.1%) | |
| Positive | 27 (56.2%) | 22 (23.7%) | |
| Failed | 0 (0.00%) | 3 (3.23%) | |
| Deposit Size | 3.68 (4.06) | 6.09 (8.66) | 0.304 |
| Extracapsular Extension | 4 (19.0%) | 7 (41.2%) | 0.167 |
| Lymphadenectomy | 15 (12.2%) | 14 (7.57%) | 0.246 |
| Tumour characteristics | | | 0.662 |
| Perineural Invasion | 10 (9.09%) | 18 (11.5%) | |
| Lymphovascular | 12 (11.0%) | 24 (15.2%) | |
| Ulceration | 26 (23.9%) | 47 (29.9%) | |
| Microsatellites | 6 (7.69%) | 15 (9.55%) | |
| Mitosis (mm²) | 3.32 (5.24) | 3.86 (5.98) | 0.398 |
| PET CT Result | | | 0.102 |
| Metastasis | 18 (60.0%) | 14 (53.8%) | |
| Oncology referral | | | <0.001 |
| No | 5 (10.9%) | 137 (74.9%) | |
| Yes | 41 (89.1%) | 46 (25.1%) | |
| Systemic Chemotherapy | | | <0.001 |
| No | 2 (10.5%) | 155 (83.8%) | |
| Yes | 17 (89.5%) | 30 (16.2%) | |



Discussion

- Internationally, melanoma diagnosis significantly decreased at the height of the pandemic in 2019¹, with early data suggesting a possible increase in subsequent tumour Breslow thicknesses².
- Early predictive models of COVID suggest an increased incidence and decrease overall survivability model of melanoma due to a delay of diagnosis worldwide³.
- Due to COVID-19, Galway University Hospital (GUH) had months of decreased elective activity and clinic availability.
- GUH plastic surgery transferred to the publicly-funded private hospital setting and implemented telemedicine clinics to continue urgent cancer services.
- The diagnosis of invasive melanoma increased during the pandemic, with no negative impact on tumour thickness, negative tumour characteristics, nodal status, or metastasis.
- This may represent a country wide success in melanoma management in comparison to neighboring European countries during the COVID-19 pandemic¹⁻³.

Tejera-Vaquerizo, A., & Nagore, E. (2020). Estimated effect of COVID-19 lockdown on melanoma thickness and prognosis: a rate of growth model. Journal of the European Academy of Dermatology and Venereology: JEADV, 34(8), e351–e353. https://doi.org/10.1111/jdv.16555



Marson JW, Maner BS, Harding TP, Meisenheimer J VII, Solomon JA, Leavitt M, Levin NJ, Dellavalle R, Brooks I, Rigel DS. The magnitude of COVID-19's effect on the timely management of melanoma and nonmelanoma skin cancers. J Am Acad Dermatol. 2021 Apr;84(4):1100-1103. doi: 10.1016/j.jaad.2020.12.065

Ricci, F., Fania, L., Paradisi, A., Di Lella, G., Pallotta, S., Sobrino, L., Panebianco, A., Annessi, G., & Abeni, D. (2020). Delayed melanoma diagnosis in the COVID-19 era: increased breslow thickness in primary melanomas seen after the COVID-19 lockdown. Journal of the European Academy of Dermatology and Venereology: JEADV, 34(12), e778–e779. https://doi.org/10.1111/jdv.16874